TSE:APHAAphria Stock Price, Forecast & News

C$6.03

+0.03 (+0.50 %)

(As of 06/2/2020 02:50 PM ET)

Add

Compare

Today's Range

C$5.88

Now: C$6.03▼

C$6.18

50-Day Range

C$4.20

MA: C$5.03▼

C$5.94

52-Week Range

C$2.65

Now: C$6.03▼

C$10.08

Volume2.73 million shs

Average Volume3.76 million shs

Market CapitalizationC$1.61 billion

P/E Ratio51.98

Dividend YieldN/A

BetaN/A

Aphria Inc. produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc. is headquartered in Leamington, Canada.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Aphria has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$8.64, Aphria has a potential upside of 42.4% from its current price of C$6.07.
Amount of Analyst Coverage
Aphria has only been the subject of 3 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Aphria has received 372 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Aphria has received 333 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Aphria has received 52.77% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Aphria and other stocks. Vote “Outperform” if you believe APHA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APHA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Aphria does not currently pay a dividend.
Dividend Growth
Aphria does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aphria insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Aphria are expected to decrease by -100.00% in the coming year, from C$0.02 to C$0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aphria is 52.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.71.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aphria is 52.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.40.
Price to Book Value per Share Ratio
Aphria has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.33 out of 5 stars

Industry, Sector and Symbol

Stock Exchange TSE

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolTSE:APHA

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.aphria.com

Phone844-427-4742

Debt

Debt-to-Equity Ratio26.02

Current Ratio5.19

Quick Ratio3.37

Price-To-Earnings

Trailing P/E Ratio51.98

Forward P/E Ratio301.50

P/E GrowthN/A

Sales & Book Value

Annual SalesC$518.70 million

Price / Sales3.11

Cash FlowC$2.00 per share

Price / Cash Flow3.02

Book ValueC$6.88 per share

Price / Book0.88

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees300

Outstanding Shares267,587,000

Market CapC$1.61 billion

Next Earnings Date7/30/2020 (Estimated)

OptionableOptionable

Receive APHA News and Ratings via Email

Sign-up to receive the latest news and ratings for APHA and its competitors with MarketBeat's FREE daily newsletter.

Aphria (TSE:APHA) Frequently Asked Questions

How has Aphria's stock been impacted by COVID-19 (Coronavirus)?

Aphria's stock was trading at C$3.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APHA shares have increased by 64.9% and is now trading at C$6.07. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aphria?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aphria in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aphria.

When is Aphria's next earnings date?

Aphria is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for Aphria.

What price target have analysts set for APHA?

5 equities research analysts have issued 1 year price objectives for Aphria's shares. Their forecasts range from C$5.30 to C$16.00. On average, they anticipate Aphria's stock price to reach C$8.64 in the next twelve months. This suggests a possible upside of 42.4% from the stock's current price. View analysts' price targets for Aphria.

Has Aphria been receiving favorable news coverage?

Press coverage about APHA stock has been trending positive on Tuesday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aphria earned a coverage optimism score of 2.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutAphria.

Who are some of Aphria's key competitors?

Some companies that are related to Aphria include Hikma Pharmaceuticals (HIK), Evotec (EVT), Aurora Cannabis (ACB), Knight Therapeutics (GUD), Ecofibre (EOF), HLS Therapeutics (HLS), OrganiGram (OGI), Hexo (HEXO), Next Science (NXS), HEXO (HEXO), ICC Labs (ICC), Amryt Pharma (AMYT), Benchmark (BMK), WeedMD (WMD) and ESSA Pharma (EPI). View all competitors.

What other stocks do shareholders of Aphria own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aphria investors own include Aurora Cannabis (ACB), Canopy Growth (WEED), Canopy Growth (CGC), Aurora Cannabis (ACB), OrganiGram (OGI), KushCo (KSHB), CannTrust (CTST), NVIDIA (NVDA), Green Organic Dutchman (TGOD) and Abattis Bioceuticals (ATT).

Who are Aphria's key executives?

Aphria's management team includes the following people:

Mr. Carl A. Merton, Chief Financial Officer
Ms. Megan McCrae, VP of Marketing
Mr. Irwin D. Simon, Interim CEO & Chairman
Mr. Jakob Ripshtein, Pres
Mr. Brett D. Marchand, Sr. VP of Operations

What is Aphria's stock symbol?

Aphria trades on the Toronto Stock Exchange (TSX) under the ticker symbol "APHA."

How do I buy shares of Aphria?

Shares of APHA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Aphria's stock price today?

One share of APHA stock can currently be purchased for approximately C$6.07.

How big of a company is Aphria?

Aphria has a market capitalization of C$1.62 billion and generates C$518.70 million in revenue each year. Aphria employs 300 workers across the globe.

What is Aphria's official website?

The official website for Aphria is www.aphria.com.

How can I contact Aphria?

Aphria's mailing address is 245 Talbot St W Suite 103, LEAMINGTON, ON N8H 1N8, Canada. The company can be reached via phone at 844-427-4742.

This page was last updated on 6/2/2020 by MarketBeat.com Staff